CG Oncology Appoints New Chief Medical Officer
Ticker: CGON · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1991792
| Field | Detail |
|---|---|
| Company | Cg Oncology, Inc. (CGON) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $20,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel, oncology
TL;DR
CG Oncology just hired a new CMO from BMS, Andy Lee. Big move for their cancer drug.
AI Summary
CG Oncology, Inc. announced on January 9, 2025, the appointment of Dr. Andrew "Andy" Lee as Chief Medical Officer. Dr. Lee, previously a Senior Vice President of Clinical Development at Bristol Myers Squibb, brings extensive experience in oncology drug development. His appointment is expected to bolster CG Oncology's efforts in advancing its lead candidate, cretostim, through clinical trials.
Why It Matters
The appointment of a seasoned Chief Medical Officer like Dr. Lee is crucial for advancing CG Oncology's drug development pipeline, potentially impacting the future success of its lead candidate and its stock value.
Risk Assessment
Risk Level: medium — The appointment of a new executive is a significant event that could impact the company's strategic direction and drug development, but the actual impact is yet to be seen.
Key Players & Entities
- CG Oncology, Inc. (company) — Registrant
- Andrew "Andy" Lee (person) — Appointed Chief Medical Officer
- Bristol Myers Squibb (company) — Former employer of new CMO
- cretostim (drug) — Lead candidate being advanced
- January 09, 2025 (date) — Date of earliest event reported
FAQ
Who has CG Oncology, Inc. appointed as their new Chief Medical Officer?
CG Oncology, Inc. has appointed Dr. Andrew "Andy" Lee as their new Chief Medical Officer.
What was Dr. Andrew Lee's previous role before joining CG Oncology, Inc.?
Before joining CG Oncology, Inc., Dr. Andrew Lee was a Senior Vice President of Clinical Development at Bristol Myers Squibb.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on January 09, 2025.
What is CG Oncology's lead candidate mentioned in the filing?
The filing mentions CG Oncology's lead candidate is cretostim.
What is the business address of CG Oncology, Inc.?
The business address of CG Oncology, Inc. is 400 Spectrum Center Drive, Suite 2040, Irvine, California 92618.
Filing Stats: 1,526 words · 6 min read · ~5 pages · Grade level 13.6 · Accepted 2025-01-10 16:15:40
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CGON The Nasdaq Global Se
- $20,000 — for 18 months, up to a maximum cost of $20,000. In addition, except with respect to
Filing Documents
- ck0001991792-20250109.htm (8-K) — 48KB
- 0000950170-25-004168.txt ( ) — 167KB
- ck0001991792-20250109.xsd (EX-101.SCH) — 26KB
- ck0001991792-20250109_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CG Oncology, Inc. Date: January 10, 2025 By: /s/ Joshua Patterson Name: Joshua Patterson Title: General Counsel and Chief Compliance Officer